A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15107
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma

American Journal of Hematology
Hematology
2017English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2014English

Outcomes in First Relapsed-Refractory Younger Patients With Mantle Cell Lymphoma: Results From the Mantle-First Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology
Hematology
2019English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Cancer
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy